RXRX vs. BEAM

Last updated Apr 1, 2026

Compare and contrast key facts about Recursion Pharmaceuticals, Inc. (RXRX) and Beam Therapeutics Inc. (BEAM).

Performance

RXRX vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

RXRX vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RXRX Recursion Pharmaceuticals, Inc.	-24.94%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%
BEAM Beam Therapeutics Inc.	-14.03%	11.77%	-8.89%	-30.40%	-50.92%	9.63%

Fundamentals

Market Cap RXRX : $1.62B BEAM : $2.50B
EPS RXRX : -$1.39 BEAM : -$0.78
PS Ratio RXRX : 19.09 BEAM : 95.90
PB Ratio RXRX : 1.43 BEAM : 2.02
Total Revenue (TTM) RXRX : $74.56M BEAM : $25.63M
Gross Profit (TTM) RXRX : $3.73M BEAM : -$284.71M
EBITDA (TTM) RXRX : -$579.69M BEAM : -$352.98M

Returns By Period

In the year-to-date period, RXRX achieves a -24.94% return, which is significantly lower than BEAM's -14.03% return.

RXRX

• 1D: 8.10%
• 1M: -16.35%
• YTD: -24.94%
• 6M: -37.09%
• 1Y: -41.97%
• 3Y*: -22.79%
• 5Y*: —
• 10Y*: —

BEAM

• 1D: 8.81%
• 1M: -16.27%
• YTD: -14.03%
• 6M: -1.81%
• 1Y: 22.02%
• 3Y*: -8.02%
• 5Y*: -21.46%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RXRX vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX

RXRX Risk / Return Rank: 17
RXRX Sharpe Ratio Rank: 20
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 13
RXRX Martin Ratio Rank: 7

BEAM

BEAM Risk / Return Rank: 52
BEAM Sharpe Ratio Rank: 53
BEAM Sortino Ratio Rank: 57
BEAM Omega Ratio Rank: 54
BEAM Calmar Ratio Rank: 47
BEAM Martin Ratio Rank: 47

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXRX vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RXRX	BEAM	Difference
Sharpe ratio Return per unit of total volatility	-0.50	0.29	-0.79
Sortino ratio Return per unit of downside risk	-0.38	1.03	-1.42
Omega ratio Gain probability vs. loss probability	0.96	1.12	-0.16
Calmar ratio Return relative to maximum drawdown	-0.81	0.19	-1.00
Martin ratio Return relative to average drawdown	-1.61	0.42	-2.03
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RXRX vs. BEAM - Sharpe Ratio Comparison

The current RXRX Sharpe Ratio is -0.50, which is lower than the BEAM Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of RXRX and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RXRX	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.50	0.29	-0.79
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.40	0.05	-0.45

Correlation

The correlation between RXRX and BEAM is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

RXRX vs. BEAM - Dividend Comparison

Neither RXRX nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RXRX vs. BEAM - Drawdown Comparison

The maximum RXRX drawdown since its inception was -93.13%, roughly equal to the maximum BEAM drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for RXRX and BEAM.

Drawdown Indicators

	RXRX	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-93.13%	-89.12%	-4.01%
Max Drawdown (1Y) Largest decline over 1 year	-58.17%	-38.15%	-20.02%
Max Drawdown (5Y) Largest decline over 5 years	—	-89.12%	—
Current Drawdown Current decline from peak	-92.57%	-82.16%	-10.41%
Average Drawdown Average peak-to-trough decline	-74.76%	-59.29%	-15.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.28%	17.33%	+11.95%

Volatility

RXRX vs. BEAM - Volatility Comparison

The current volatility for Recursion Pharmaceuticals, Inc. (RXRX) is 14.77%, while Beam Therapeutics Inc. (BEAM) has a volatility of 17.93%. This indicates that RXRX experiences smaller price fluctuations and is considered to be less risky than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RXRX	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.77%	17.93%	-3.16%
Volatility (6M) Calculated over the trailing 6-month period	54.53%	53.97%	+0.56%
Volatility (1Y) Calculated over the trailing 1-year period	84.44%	78.23%	+6.21%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.56%	75.45%	+19.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	94.56%	80.57%	+13.99%

Financials